By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News)– Qiagen today announced that Japanese regulators have approved the company's Therascreen EGFR Mutation Detection Kit as a companion diagnostic for drugs targeting non-small cell lung cancer.

Separately, it also said that it has acquired the rights to biomarkers from two US firms for applications in personalized treatment of various cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.